Authors
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Clinical Pearls on Recent Advances and the Future of Treatment in RCCMehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Latest:
Deepu Madduri, MD, on Research in Multiple Myeloma This Past YearThe expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
Latest:
Liso-Cel Yields Long-Lasting Complete Responses in Heavily Pretreated MCLTreatment with liso-cel appears to result in clinically meaningful activity across several subgroups of patients with mantle cell lymphoma, including those with high-risk features.
Latest:
Pomalidomide Combo Shows Deep, Enduring Responses in R/R Multiple MyelomaData from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.
Latest:
Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLLBulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Latest:
Pembrolizumab/Lenvatinib Elicits Meaningful Responses in High-Grade Serous PROCA phase 2 trial found that pembrolizumab plus lenvatinib elicited an overall response rate of 37.5% that consisted entirely of partial responses in high-grade serous PROC.
Latest:
Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate CancerMuhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
Latest:
Exploring Treatment Options Through Genomic Sequencing in Endometrial CancerRisk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.
Latest:
Effectiveness, Toxicity, and Survival Predictors of Regorafenib in Metastatic Colorectal Cancer: A Multicenter Study of Routinely Collected DataAlberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Latest:
Ubamatamab, Anti-PD-1 ICI, May Bolster Immune Response in Kidney CancerA phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Latest:
Abdulraheem Yacoub, MD, on Advancing Outcomes for Patients With Myelofibrosis and Myeloproliferative NeoplasmsCancerNetwork® spoke with Abdulraheem Yacoub, MD, during the American Association for Cancer Research Annual Meeting 2021 to discuss how predictors of response to therapy may be just as important as the development of new therapies for advancing outcomes in myelofibrosis and myeloproliferative neoplasms.
Latest:
Expert Commentary on the Product Profile of Margetuximab for HER2-Positive Breast CancerIn an interview with ONCOLOGY®, Sandra Cuellar, PharmD, BCOP, FASHP, offers a comprehensive review of real-world treatment considerations of margetuximab as therapy for adult patients with metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 regimens with at least 1 being for metastatic disease.
Latest:
Retrospective Radiotherapy in IBD Data May Warrant Prospective ResearchRetrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Latest:
Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBICuMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Latest:
The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer TreatmentThe panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
Latest:
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaThis study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
